Predictive Oncology (NASDAQ:AGPU) Stock Price Down 13.6% – Should You Sell?

Predictive Oncology Inc. (NASDAQ:AGPU)’s share price dropped 13.6% during mid-day trading on Thursday . The company traded as low as $5.57 and last traded at $5.60. Approximately 378,708 shares changed hands during mid-day trading, a decline of 92% from the average daily volume of 4,758,807 shares. The stock had previously closed at $6.48.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Predictive Oncology in a research note on Friday, April 24th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Predictive Oncology Trading Down 13.6%

The stock has a market cap of $31.02 million, a P/E ratio of -0.44 and a beta of 3.45. The company has a fifty day moving average of $3.78.

Predictive Oncology (NASDAQ:AGPU) last announced its earnings results on Tuesday, March 31st. The company reported $122.75 earnings per share (EPS) for the quarter. The business had revenue of $0.01 million during the quarter.

About Predictive Oncology

Predictive Oncology (NASDAQ: AGPU) is a biotechnology company focused on oncology-related research and product development that combines laboratory science with data analytics. The company positions itself to support precision medicine by applying computational methods and laboratory testing to better understand tumor biology and to accelerate the identification and development of oncology therapeutics and diagnostics.

Its activities include laboratory-based testing and analytic services intended to inform drug discovery and development, biomarker identification, and patient stratification efforts.